
At Skaaltec, our mission is to drive good health universally. We are dedicated to providing advanced neuroscience-inspired solutions, with a focus on brain health, mobility and neurotechnology. Our flagship project is the SmartVNS - an intelligent Vagus nerve stimulation (VNS) system. Our vision for SmartVNS is to transform daily life into effective therapy. SmartVNS is a pioneer medical device that not only helps patients recover faster, but also crucially follow patients from the bedside to home and is ideally suited for remote therapy.

At Skaaltec, our mission is to drive good health universally. We are dedicated to providing advanced neuroscience-inspired solutions, with a focus on brain health, mobility and neurotechnology. Our flagship project is the SmartVNS - an intelligent Vagus nerve stimulation (VNS) system. Our vision for SmartVNS is to transform daily life into effective therapy. SmartVNS is a pioneer medical device that not only helps patients recover faster, but also crucially follow patients from the bedside to home and is ideally suited for remote therapy.
Product: SmartVNS — a non‑invasive, wearable vagus nerve stimulation system integrating sensing, motion analysis, algorithms/AI, and stimulation control for post‑stroke arm recovery.
Stage: Early-stage, grant-funded (reported Feb 2024 grant CHF 10.0k).
Founders / Leadership: Co‑founders Paulius Viskaitis (CEO) and Dane Donegan (CSO), both listed as neuroscientists (Dr.).
Origin: ETH Zürich spin‑off (reported 2023).
Headquarters: Zurich, Switzerland (Balgrist Campus).
Team size: Approximately 8 employees (reported).
Neurorehabilitation for post‑stroke motor (arm) recovery.
2023
Medtech; Neurorehabilitation
CHF 10.0k
Reported as a grant round in third‑party company databases.
“Grant‑stage support from EPFL Innovation Park and the Future of Health Grant; profile listings also reference participation with other foundations (e.g., Gebert Rüf Foundation).”
| Company |
|---|